As a descendant of an Indigenous Amazonian tribe, Maria Astolfi was concerned about research she conducted as a graduate ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

As reported in our April 25, 2025, blog item, the National Security Commission on Emerging Biotechnology (NSCEB) announced on April 8, 2025, the availability of its final report and action plan, “ur ...

From STAT’s Jason Mast: Moderna said this morning in its earnings report it planned to cut costs by around $1.5 billion by ...

The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.

Fermenta Biotech Limited (Fermenta) proudly steps into its 75th year, beginning a momentous chapter in its journey of trust, ...

A research team has uncovered a previously unknown type of immune signaling molecule—a novel compound combining histidine and ...

Cyprus Seeds and The Cyprus Institute of Neurology & Genetics organized on April 29th 2025, an inspirational speech, “A ...

Eascra's proprietary technology, pioneered by co-founder Dr. Yupeng Chen, can deliver RNA therapeutics to hard-to-reach ...

We unpack the full scope of the U.S. budget cuts, from canceled clinical trials and stalled drug approvals to mass layoffs ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...